Magnotherapy — Cost, Top Hospitals & Success Rates | MyMedicPlus

'Magnotherapy' is a broad umbrella term encompassing several distinct modalities that use magnetic fields for therapeutic purposes. These range from static permanent magnets worn on the body — a traditional practice with minimal scientific support — to sophisticated, FDA-approved medical technologies that deliver precisely controlled magnetic fields to the brain and body for serious neurological and orthopaedic conditions. Understanding the evidence base for each modality is essential, as they differ dramatically in mechanism, clinical evidence, regulatory approval status, and therapeutic validity.

The four principal magnetic therapy modalities are:

1. Static (permanent) magnet therapy — magnets embedded in wristbands, insoles, mattress pads, and jewellery; marketed for pain, fatigue, and general health. No convincing evidence beyond placebo in Cochrane-level systematic reviews.
2. Pulsed Electromagnetic Field Therapy (PEMF) — low-frequency alternating electromagnetic fields applied externally to tissues. FDA-cleared for non-union bone fractures (1979), and with Level II evidence for knee osteoarthritis and wound healing.
3. Transcranial Magnetic Stimulation (TMS / rTMS) — rapidly changing strong magnetic fields delivered to the scalp by a coil, inducing electric currents in the cortex. FDA-cleared for major depressive disorder (2008), OCD (2018), anxious depression (2021), and smoking cessation (2020). The strongest evidence base of any non-invasive brain stimulation technique.
4. MRI-guided Focused Ultrasound (MRgFUS) — not magnetic therapy per se, but uses a strong magnetic field (MRI) for real-time spatial guidance and thermometry of high-intensity focused ultrasound (HIFU) beams that ablate deep brain targets. FDA-approved for essential tremor, Parkinson tremor, and OCD. The most evidence-based application of magnetic guidance in therapeutic medicine.

This guide addresses each modality in terms of mechanism, evidence quality, regulatory status, patient selection, and clinical role — enabling patients and clinicians to distinguish evidence-based magnetic medicine from unproven complementary claims.

Static Magnet Therapy — Claimed Indications (Evidence-Deficient):

Proponents of static magnet therapy claim benefits for: chronic musculoskeletal pain (osteoarthritis, fibromyalgia, low back pain), carpal tunnel syndrome, peripheral neuropathy, fatigue, insomnia, and general 'energy balance.' These claims are not substantiated by high-quality randomised controlled trial evidence. The theoretical mechanism — that permanent magnets increase blood flow via effects on paramagnetic haemoglobin — has been refuted; the magnetic fields of consumer products (typically 10–500 mT at the surface) are far too weak and superficial to penetrate tissues or influence haemodynamics at clinically relevant depths.

PEMF — Approved and Investigated Indications:

• Non-union and delayed bone healing fractures: The most evidence-supported PEMF indication. FDA-cleared since 1979 (OrthoLogic/EBI Medical). Mechanism: low-frequency (1–100 Hz) alternating magnetic fields induce weak electric currents in piezoelectric bone matrix, stimulating osteoblast activity and calcium signalling. RCT data and systematic reviews demonstrate modest but significant improvement in fracture union rates in established non-unions (~70% union rate with PEMF vs ~50% surgery alone in some series).
• Knee osteoarthritis: Level II evidence (multiple RCTs, though heterogeneous) for pain reduction and functional improvement. PEMF (50–100 Hz, 1–3 mT) applied for 4–8 hours/day for 4–12 weeks shows statistically significant but clinically modest effects on VAS pain and WOMAC scores.
• Wound healing: FDA-cleared for wound healing adjunct in chronic pressure ulcers and diabetic foot wounds — some RCT support.
• Post-operative pain and oedema: Pulsed shortwave diathermy (PSWD) — a high-frequency PEMF variant — used in physiotherapy for soft tissue injury, bursitis, and post-surgical swelling reduction.

TMS / rTMS — FDA-Cleared Indications (Highest Evidence Level):

• Major depressive disorder (MDD): Treatment-resistant depression (TRD) — inadequate response to ≥1 antidepressant. Standard protocol: 10 Hz high-frequency rTMS to left dorsolateral prefrontal cortex (DLPFC) × 4–6 weeks (36 sessions, daily). Response rate: ~50–60%; remission: ~30–35% (NeuroStar pivotal trials).
• OCD: Deep TMS (dTMS) to the medial prefrontal cortex/anterior cingulate — FDA-cleared 2018 (BrainsWay H7 coil). DYBBS OCD trial: significant Y-BOCS score reduction in symptom provocation protocol.
• Anxious depression: FDA-cleared 2021 (NeuroStar system for MDD with comorbid anxiety).
• Smoking cessation: FDA-cleared 2020 (dTMS H4-coil targeting bilateral prefrontal and insular cortex); 4-week abstinence rates approximately doubled vs sham.
• Migraine prevention: Single-pulse TMS (sTMS — eNeura device) FDA-cleared for acute migraine treatment and prevention. The ESPOUSE study demonstrated significant monthly migraine day reduction.
• Post-stroke motor rehabilitation: Inhibitory rTMS (1 Hz) to contralesional hemisphere to reduce interhemispheric inhibition and facilitate paretic limb recovery. Multiple RCTs support use as adjunct to conventional physiotherapy.

MRgFUS — FDA-Approved Indications:

• Essential tremor: FDA-approved 2016 (Insightec Exablate Neuro) — thalamotomy of the ventral intermediate nucleus (VIM) of the thalamus. Superior to sham in pivotal trial (72% improvement in tremor score at 3 months; maintained at 5 years).
• Parkinson's disease tremor: FDA-approved 2018 for VIM thalamotomy targeting tremor-dominant PD. Bilateral treatment now approved (staged procedures).
• OCD (capsulotomy): FDA-approved 2023 for anterior limb of the internal capsule ablation in refractory OCD.
• Uterine fibroids: FDA-approved (ExAblate system) for symptomatic uterine fibroids — shrinkage and symptom improvement without surgery.

Static Magnet Therapy — Eligibility:

No formal patient selection criteria exist as static magnet therapy is an over-the-counter product. Contraindications are practical: patients with cardiac pacemakers, implantable cardioverter-defibrillators (ICDs), and other electromagnetic implants should avoid strong static magnets near the device. Pregnant women should exercise caution. The principal risk, however, is not physical harm but rather delay of effective medical treatment by pursuing unproven therapy instead of evidence-based care.

PEMF Therapy — Patient Selection:

• Indicated for: Established fracture non-union (>3 months without radiological healing); delayed union; avascular necrosis of femoral head (investigational); knee OA with inadequate response to first-line analgesia and physiotherapy.
• Contraindications: Active cancer (concern about stimulating tumour cell proliferation — data limited but caution advised); pregnancy; implanted electrical devices (pacemakers, cochlear implants, spinal cord stimulators) — risk of device interference; active joint infection; coagulopathy.

TMS/rTMS — Patient Selection (Rigorous Clinical Assessment Required):

• Major depressive disorder: FDA-cleared indication requires: formal psychiatric diagnosis of MDD; failure of adequate trial of ≥1 antidepressant at therapeutic dose for ≥6 weeks; absence of active suicidality requiring inpatient care; QIDS-SR or PHQ-9 documentation of severity.
• Contraindications (absolute): Metallic intracranial implants (aneurysm clips, cochlear implants, deep brain stimulator leads within the coil field); metallic objects within 30 cm of the coil (facial piercings, non-MRI-compatible implants). Cardiac pacemakers and ICDs are NOT absolute contraindications to TMS (unlike MRI), but require cardiology consultation.
• Relative contraindications: Personal history of seizures or epilepsy (rTMS can lower seizure threshold — requires neurological evaluation and seizure risk stratification); current use of medications that significantly lower seizure threshold (clozapine, tramadol, bupropion at high dose); active substance use disorder; pregnancy (limited data — generally avoided except in severe cases). History of head injury, CNS tumour, or neurosurgical procedure requires individual risk assessment.

MRgFUS — Strict Patient Selection:

• Tremor-dominant disease refractory to medication (≥2 medications at adequate dose); unilateral treatment preferred to avoid bilateral cerebellar complications.
• Patient must be able to remain awake in MRI scanner for 2–4 hours (closed bore MRI required for thermometry).
• Skull density ratio (SDR) ≥0.45: skull bone quality (measured by CT) must be sufficient to allow adequate ultrasound transmission — approximately 15–20% of patients are excluded by poor SDR.
• Absolute contraindications: bilateral treatment at same session (risk of bilateral ataxia and dysarthria — staged procedures only); active deep brain stimulator; significant coagulopathy; pregnancy; pacemaker or MRI-incompatible implant.

Static Magnet Therapy — Consumer Products:

Static magnets are available as wristbands (e.g., Bioflow, Trion:Z), magnetic mattress pads, shoe insoles, back braces, and necklaces, typically marketed with field strengths of 100–3,000 gauss (10–300 mT). No standardised dosing protocol or evidence-based device specification exists. Consumer prices range from USD 20–500. The mechanism claimed (improving circulation via haemoglobin magnetism) is biologically implausible at available field strengths — deoxyhaemoglobin is paramagnetic, but in-vivo red blood cell flow is not significantly influenced by consumer product field strengths at tissue depth.

PEMF Therapy Protocols:

• Bone healing devices (FDA-cleared): OrthoLogic OL1000 and EBI Bone Healing System deliver low-frequency (75 Hz) PEMF via non-invasive coils applied externally around the fracture site. Typical protocol: 3 hours/day for 3–6 months. Patients can perform treatment at home.
• Clinical-grade PEMF (inpatient/outpatient physiotherapy): Devices such as Curatron, iMRS 2000 (Omnium1), and Biomag deliver variable frequency (1–300 Hz) and intensity (0.01–300 µT) fields via full-body or localised applicators. Sessions typically 8–30 minutes, 3–5 times per week for 4–12 weeks.
• Pulsed shortwave therapy: Delivered at 27.12 MHz (shortwave frequency) in pulsed mode; used by physiotherapists for soft tissue injury, arthritis, and post-operative recovery.

rTMS Protocols for Depression:

• Standard 10 Hz high-frequency left DLPFC protocol (FDA-cleared): 3,000 pulses/session (40 trains of 75 pulses at 10 Hz, 4-second on/26-second off) × 36 sessions (5 days/week for ~7.5 weeks). Motor threshold determination at first session individualises stimulation intensity (typically 120% of resting motor threshold — RMT).
• Theta-burst stimulation (iTBS) — intermittent TBS: A compressed protocol delivering 600 pulses in just 3 minutes vs 37 minutes for standard 10 Hz rTMS. Non-inferior to standard rTMS for depression (THREE-D trial, Canada, n=414). iTBS uses triplets of 50 Hz pulses at 5 Hz theta frequency. Enables higher daily throughput at TMS centres.
• SAINT Protocol (Stanford Accelerated Intelligent Neuromodulation Therapy): The most rapidly acting and highest-remission TMS protocol studied to date. Delivers 10 sessions of iTBS per day (each 3 minutes, separated by 50-minute intervals) for 5 consecutive days — 50 sessions total over 1 week. Uses functional MRI-guided targeting of the left DLPFC subregion most anti-correlated with the subgenual cingulate cortex. The pivotal SAINT RCT (Cole et al., Am J Psychiatry 2022, n=29) demonstrated 78.6% remission rate (HAMD-17 <8) at 4 weeks vs 13.3% in sham — a transformative result in treatment-resistant depression. Larger confirmatory trials and commercial implementation (Magnus Medical BrainsWay system) now underway. Promising data also in MDD with suicidality and eating disorders.
• Deep TMS (dTMS) — BrainsWay H-coil: H-coil geometry penetrates deeper brain structures (4–6 cm) vs figure-8 coil (2–3 cm). FDA-cleared for depression, OCD, anxious depression, and smoking cessation with specific H-coil configurations.

MRgFUS Procedure:

MRgFUS for essential tremor or Parkinson tremor is performed in a single session of 2–4 hours, awake, in a 3T MRI scanner. A stereotactic frame is fixed to the skull; a transducer helmet with 1,024 ultrasound elements is positioned around the head. The thalamic target (VIM or zona incerta for tremor) is identified on MRI. Low-power sonications are performed incrementally, with the patient assessed for tremor improvement and side effects (paraesthesiae, instability) after each sonication. Temperature at the focus is monitored in real-time by MR thermometry — treatment is complete when target temperature reaches 54–60°C for tissue ablation. No incision, no radiation, no general anaesthesia. Bilateral staged procedures (with 6-month interval) are approved for essential tremor with bilateral disability.

The evidence base for magnetic therapies varies dramatically by modality:

Static Magnet Therapy — Evidence Assessment: NEGATIVE

The most comprehensive systematic review — the Cochrane review by Pittler et al. (2007, updated 2009) — examined 29 RCTs of static magnet therapy for pain conditions. Conclusion: 'The evidence does not support the use of static magnets for pain relief, and therefore magnets cannot be recommended as an effective treatment.' Multiple individual RCTs using validated placebo magnets (identical appearance but demagnetised) show no significant difference in pain outcomes between active and placebo magnets for osteoarthritis, fibromyalgia, plantar fasciitis, or wrist pain. Any perceived benefit from consumer magnetic products is likely attributable to placebo effect, natural disease course, or concurrent conventional treatments.

PEMF — Evidence Assessment: MODEST, CONDITION-SPECIFIC

• Bone non-union: FDA-cleared; multiple RCTs and meta-analyses support clinical utility. A Cochrane review (Griffin et al.) found PEMF to be a reasonable adjunct to surgical management of fracture non-union with acceptable evidence quality (Level II). Clinical bone healing success rate improvement of 15–20% over control.
• Knee osteoarthritis: 2020 meta-analysis (Nindl et al.) of 19 RCTs (n=1,200): significant reduction in VAS pain (SMD −0.69, 95% CI −1.03 to −0.35) and improvement in WOMAC function. Effect size is moderate and clinically meaningful for patients with inadequate response to pharmacotherapy. Level II evidence.
• Overall PEMF assessment: A legitimate adjunctive therapy with an FDA-cleared role in specific indications, but with a heterogeneous evidence base and limited long-term follow-up data. Not a replacement for conventional orthopaedic management.

rTMS for Depression — Evidence Assessment: STRONG, FDA-CLEARED

• Multiple large RCTs and meta-analyses establish rTMS as an effective treatment for MDD. The landmark O'Reardon et al. (2007) multisite RCT (n=325) was pivotal for FDA clearance. Subsequent real-world data (e.g., NeuroStar TMS Patient Registry, n=2,610): response rate 58.1%, remission rate 37.1% — markedly superior to the approximately 10–15% response rate seen in further pharmacological trials after two antidepressant failures.
• The SAINT protocol (Cole et al. 2022) achieves 78.6% remission in TRD within 5 days — the fastest and highest remission rate ever reported for a non-pharmacological depression treatment.
• Maintenance TMS (monthly 'booster' sessions) prolongs remission duration and reduces relapse risk; evidence from observational and small RCT data supports the practice.

MRgFUS — Evidence Assessment: STRONG, FDA-APPROVED

• Elias et al. (2016, NEJM, n=76): MRgFUS thalamic ablation for essential tremor achieved significant tremor improvement (47% improvement in tremor score) vs 0% sham at 3 months; maintained at 5-year follow-up (Meng et al. 2018).
• Parkinson tremor: MRgFUS thalamotomy achieves >50% tremor reduction in ~80% of patients at 1 year.
• OCD (capsulotomy): Phase III trial data demonstrated significant Y-BOCS improvement in refractory OCD.

Static Magnet Therapy — Safety:

Static consumer magnets in themselves pose minimal direct health risk to healthy individuals. The principal safety concerns are: (1) interference with pacemakers and ICDs — strong magnets placed within 15 cm of these devices can trigger magnet mode; (2) interference with cochlear implants; (3) serious risk of delay of effective medical treatment when patients choose magnets instead of evidence-based care for serious conditions. No significant biological adverse effects from static magnet products have been documented in the scientific literature.

PEMF — Adverse Effects:

• Generally well-tolerated; most adverse effects are mild: skin irritation at electrode contact site, mild warmth, tingling.
• Risk of interference with implanted electrical devices (pacemakers, ICDs, deep brain stimulators, intrathecal drug pumps) — contraindication.
• Theoretical concern regarding PEMF use over active neoplastic tissue — not contraindicated by FDA but generally avoided by clinicians pending further safety data.
• No convincing evidence of carcinogenicity or genotoxicity from low-frequency PEMF at therapeutic field strengths in systematic reviews (IARC classifies ELF magnetic fields as Group 2B — possibly carcinogenic — based on epidemiological associations with childhood leukaemia at residential exposures, but not at PEMF therapeutic levels or durations).

rTMS — Adverse Effects and Contraindications:

• Seizure: The most serious adverse event — risk is approximately 1 in 10,000 sessions with standard clinical protocols. Occurs predominantly when contraindications are violated (seizure disorder, seizure-threshold-lowering medications). Standard protocols following published safety parameters (Rossi et al. TMS Safety Guidelines) are associated with very low seizure risk in screened patients.
• Headache and scalp discomfort: Most common side effect (30–50% of patients); transient, typically resolves with ibuprofen and subsides after the first week of treatment.
• Syncopal episode (vasovagal): Rare; patients are treated seated.
• Transient hearing discomfort: The clicking sound of the TMS coil (100+ dB) requires foam ear protection for every session.
• Mania induction: Risk in bipolar disorder — TMS is used with mood stabiliser cover in carefully selected bipolar depression patients.
• Regulatory status: rTMS devices are FDA Class II medical devices requiring prescription and administration by trained clinicians. Consumer 'TMS devices' sold online for home use are not FDA-cleared for any indication and carry unregulated risk.

MRgFUS — Adverse Effects:

• Ataxia and gait instability: Occurs in 20–40% of patients acutely; mostly transient (resolves within 1 month in 80–90%). Persistent ataxia in 5–10% — risk increases with bilateral treatment. Patients advised not to drive for 48 hours.
• Paraesthesiae: Contralateral face, lip, or hand tingling (somatosensory thalamus adjacency to VIM); persists in ~5–10%.
• Dysarthria: Rare with unilateral VIM procedure; risk with bilateral thalamic ablation.
• Skull heating: Skin burns at scalp/skull interface in early-generation systems; rare with modern cooling systems.
• Headache: During/immediately after procedure; transient.
• Long-term durability: At 5 years, approximately 75–80% maintain significant tremor benefit; 20–25% experience some tremor recurrence. Repeat MRgFUS or addition of deep brain stimulation (DBS) for recurrence is feasible.

Static Magnet Therapy:

No clinical follow-up protocol is recommended or required by regulatory bodies for static magnet products — they are unregulated consumer devices in most jurisdictions. Patients using static magnets for pain management should be reviewed by their general practitioner or specialist to ensure: (1) an accurate diagnosis has been established; (2) evidence-based first-line treatments have been offered and optimised; and (3) the magnet use is not delaying diagnosis or treatment of a serious underlying condition (e.g., malignancy, inflammatory arthritis).

PEMF for Bone Non-Union:

• Radiological assessment of fracture union (plain X-ray, CT) at 6 weeks, 3 months, and 6 months of PEMF treatment.
• If no radiological union at 6 months of compliant PEMF therapy, reassessment for surgical intervention (intramedullary nailing, bone grafting, internal fixation).
• Patient compliance monitoring — PEMF bone devices record treatment hours; devices returned and compliance data reviewed at each visit.

TMS for Depression:

• Clinical assessment of depressive symptoms (QIDS-SR, PHQ-9) before first session and at sessions 10, 20, 30, and 36 (end of acute course).
• Response assessment at treatment end: response = ≥50% reduction in QIDS-SR; remission = QIDS-SR ≤5. Non-responders at session 20 may have target or protocol adjusted.
• Post-acute treatment: maintenance rTMS (typically weekly tapered to monthly) for patients in remission to prevent relapse. Duration: 6–12 months of maintenance for first remission; indefinite for recurrent TRD.
• Psychiatric medication review in conjunction with TMS — combination of rTMS and antidepressant pharmacotherapy may be synergistic.
• SAINT protocol post-treatment monitoring at 1 month (primary endpoint in Cole 2022 trial) and 3-monthly thereafter.

MRgFUS Follow-Up:

• Clinical tremor assessment (CRST — Clinical Rating Scale for Tremor) at 1 week, 1 month, 3 months, 6 months, and annually post-procedure.
• MRI brain at 24–48 hours post-procedure to confirm ablation lesion location (target: focal hyperintensity at VIM on T1/T2).
• Gait and neurological assessment (looking for ataxia, dysarthria, dysphagia) at each visit.
• Quality of life assessment (SF-36, QUEST — Quality of Life in Essential Tremor) at 3, 12, 24 months.
• Management of recurrent tremor: medications (propranolol, primidone) re-trialled; DBS may be considered for focal ablation retreatment limitations.

Static Magnet Products:

Consumer magnetic products range from USD 20–500 depending on product type (wristband, mattress pad, etc.). No prescription required; sold online and in health food stores globally. Not reimbursable by health insurance in any major jurisdiction, as no evidence of clinical effectiveness supports coverage. Patients spend an estimated USD 1–5 billion per year globally on magnet therapy products (consumer health market estimate).

PEMF Therapy:

• Clinical PEMF sessions: USD 50–150 per session in physiotherapy clinics; packages of 10–20 sessions commonly offered. Total course cost: USD 500–3,000.
• PEMF bone healing devices: USD 2,000–4,000 for home rental (OrthoLogic OL1000) in the USA; covered by Medicare under DMEPOS benefit for FDA-cleared fracture non-union indications with prior authorisation.
• Consumer PEMF mats (iMRS, Curatron, MRS 2000): USD 1,500–10,000 for purchase; not covered by insurance.

rTMS for Depression:

• A full acute course (36 sessions over 7–9 weeks): USD 6,000–15,000 total in the USA. Insurance coverage varies: Medicare covers rTMS for MDD (with prior authorisation documenting antidepressant failure); commercial insurance plans vary but most major insurers now provide coverage for FDA-cleared indications.
• SAINT protocol (accelerated iTBS): Currently USD 10,000–20,000 at specialised centres; limited insurance coverage but expanding as trial data becomes incorporated into guidelines.
• In the UK, rTMS is available on the NHS for treatment-resistant depression under NICE interventional procedure guidance (IPG 542, updated 2015); provision is variable by trust. Private rTMS clinics charge GBP 200–350 per session in the UK.
• In India, rTMS is available at major psychiatric hospitals and some corporate hospitals at INR 2,000–5,000 per session (USD 25–65).

MRgFUS:

• USA: USD 20,000–35,000 for the procedure at academic and community centres. Medicare covers MRgFUS for essential tremor and Parkinson tremor under specific CPT codes. Commercial coverage varies.
• UK (NHS): Available at selected neurosurgical centres for essential tremor (NICE HST10 guidance, 2019) and Parkinson tremor; waiting lists may apply.
• South Korea and Japan: MRgFUS broadly available; costs approximately USD 15,000–25,000 at specialised centres.

Patients considering magnetic therapies should be aware of the evidence-based alternatives for each target condition:

Alternatives to Static Magnet Therapy for Pain:

• Osteoarthritis: Exercise therapy and weight management (highest evidence — NICE NG226); topical NSAIDs (diclofenac gel — strong RCT evidence); intra-articular corticosteroid or hyaluronic acid injections; duloxetine; knee replacement surgery for severe OA. Acupuncture has modest evidence for short-term pain relief (Cochrane — small but clinically significant effect over sham).
• Chronic low back pain: Exercise (aerobic, stretching, strengthening — Cochrane Level I evidence); cognitive-behavioural therapy; NSAIDs; spinal cord stimulation for neuropathic component; mindfulness-based stress reduction.
• Fibromyalgia: Aerobic exercise (strongest evidence); pregabalin, duloxetine, milnacipran (FDA-approved); CBT; multidisciplinary pain management programmes.

Alternatives for Fracture Non-Union (vs PEMF):

• Surgical: revision intramedullary nailing, bone grafting (autologous iliac crest or synthetic bone graft substitutes), exchange nailing, plate fixation, external fixation with bone transport (for infected non-union — Ilizarov technique), cortical bone allograft.
• Biological augmentation: platelet-rich plasma (PRP — evidence limited), bone morphogenetic protein (BMP-2 or BMP-7 — FDA approved for specific tibial non-union and spinal fusion).
• Low-intensity pulsed ultrasound (LIPUS — Exogen device): Alternative non-surgical approach with modest evidence for delayed union; FDA-cleared, similar evidence tier to PEMF.

Alternatives for Treatment-Resistant Depression (vs rTMS):

• Esketamine (Spravato): Intranasal NMDA antagonist; FDA-approved 2019 for TRD and MDD with suicidal ideation. Administered in certified healthcare settings (REMS programme). Rapid-acting antidepressant — significant response within 24 hours in many patients. Combination with oral antidepressant.
• Electroconvulsive therapy (ECT): The most effective treatment for severe, life-threatening, or psychotic depression — response rates 60–80%, superior to rTMS for immediate severe episodes. Requires general anaesthesia; memory side effects (primarily anterograde) are the main limitation. Maintenance ECT prevents relapse.
• Psilocybin-assisted psychotherapy: Phase III trials in progress (COMP360, MAPS psilocybin); currently approved in Australia (TGA, 2023) and used in research settings in the USA and UK. Promising rapid and durable antidepressant effects in TRD, but regulatory availability is limited.
• Deep brain stimulation (DBS): Implanted electrodes to subcallosal cingulate cortex or medial forebrain bundle for ultra-refractory TRD; reserved for the most severe, unresponsive cases.

Alternatives for Tremor (vs MRgFUS):

• Pharmacotherapy: propranolol, primidone, gabapentin (essential tremor); levodopa/carbidopa (Parkinson tremor); clonazepam (orthostatic tremor).
• Deep brain stimulation (DBS) of VIM nucleus: the gold-standard surgical intervention for tremor; bilateral treatment possible; adjustable and reversible; hardware infection risk ~2–4%. Superior for patients with dystonic or complex tremors. MRgFUS avoids hardware implantation but cannot be adjusted.
• Radiosurgical thalamotomy (Gamma Knife): non-invasive radiosurgical ablation of VIM; less precise than MRgFUS (no real-time feedback); delayed effect (6–12 months); radiation dose limits retreatment.